Patent classifications
A61K2039/60
VACCINE DELIVERY SYSTEMS USING YEAST CELL WALL PARTICLES
The present invention generally relates to compositions and methods for delivering a vaccine. The compositions and methods disclosed herein are particularly useful in making prophylactic and therapeutic vaccines.
VACCINE NANOTECHNOLOGY
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or in B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at least one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof.
PEPTIDE DISPLAYING BACTERIOPHAGE NANOPARTICLES AND RELATED COMPOSITIONS AND METHODS
Described herein is a fusion protein comprising a bacteriophage protein fused to a cancer antigen. Vaccines are also described, as well as methods of treatment and/or prevention of cancer and methods of immunizing an individual.
ORAL COMPOSITION AND METHODS FOR IMMUNOTHERAPY
A composition includes a metal chemically bound to at least one heat-denatured tumor antigen and at least one heat-denatured alloantigen. The tumor antigen and/or the alloantigen are hydrolyzed. The composition can be formulated in a tablet or pill. Methods of treatment of cancer and inflammatory diseases are also provided by administering, e.g., orally, the composition to a subject in need thereof.
Gas-filled microvesicles for use as vaccine
Gas-filled microvesicles comprising an antigen bound thereto and to aqueous suspensions containing said microvesicles, for use in immunomodulating formulations, in particular as a vaccine. The antigen is covalently bound to a component of the microvesicles envelope. The microvesicles of the invention, comprising a molar excess of fatty acids in the stabilizing envelope, are particularly effective in the uptake by antigen-presenting cells, in particular dendritic cells.
VACCINES AGAINST HEPATITIS B VIRUS
A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (BMC) from at least one chronically infected HBV individual in an 10 in vitroassay.
Methods and compositions for treating multiple sclerosis and related disorders
This disclosure provides therapeutic compositions and methods for treating multiple sclerosis or a multiple sclerosis-related disorder in a subject in need thereof comprising administering an effective amount of an antigen-MHC-nanoparticle complex to the subject, wherein the antigen is a multiple sclerosis-related antigen.
NON-GENETIC MODIFICATION OF ENVELOPED VIRUSES
The invention concerns a modified enveloped virus wherein said virus has at least one anti-tumor, tumor-specific peptide non-genetically attached to or inserted in/through the viral envelope; a pharmaceutical composition comprising same; and a method of treating cancer using same.
Peptide vaccine formulations and use thereof for inducing an immune response
Embodiments of a novel platform for delivering a peptide antigen to a subject to induce an immune response to the peptide antigen are provided. For example, nanoparticle polyplexes are provided that comprise a polymer linked to a peptide conjugate by an electrostatic interaction. The conjugate comprises a peptide antigen linked to a peptide tag through an optional linker. An adjuvant may be included in the nanoparticle polyplex, linked to either the polymer or the conjugate, or admixed with the nanoparticles. The nanoparticle polyplex can be administered to a subject to induce an immune response to the peptide antigen.
Nanoscale artificial antigen presenting cells
This disclosure provides nano-scale Artificial Antigen Presenting Cells (aAPC), which deliver stimulatory signals to lymphocytes, including T-helper lymphocytes, for use as a powerful tool for immunotherapy.